Baseline parameters (recorded before age 3 years), AAE rate, eICA stenosis, and SCI in the 3 different groups of initially applied treatment
| Characteristic . | TP1, mean (SD) . | HU+TP2, mean (SD) . | None, mean (SD) . | Comparison (P) . | ||
|---|---|---|---|---|---|---|
| Intracranial macrovasculopathy (n = 51) . | Frequent VOC/ACS (n = 55) . | Less severe (n = 83) . | TP1 vs none . | HU+TP2 vs none . | Intensified vs none . | |
| White blood cell | 16.5 (5.5) | 14.4 (4.7) | 13.2 (4.1) | .001* | .152 | .002* |
| Hb | 7.7 (0.9) | 8.2 (1.2) | 8.5 (1.3) | <.001* | .124 | .002* |
| Mean corpuscular volume | 80.5 (7.7) | 78.5 (9.3) | 75.9 (9.7) | .004* | .150 | .012* |
| Reticulocyte count | 363 (149) | 290 (100) | 256 (92) | <.001* | .071 | <.001* |
| Platelets | 345 (144) | 372 (153) | 344 (110) | .817 | .288 | .405 |
| LDH | 935 (396) | 826 (390) | 681 (293) | .002* | .058 | .001* |
| HbF | 14.4 (7.8) | 13.9 (7.1) | 17.7 (8.8) | .038* | .014* | .008* |
| AAE rate | 0.24 (0.44) | 0.21 (0.43) | 0.12 (0.26) | .082 | .182 | .044* |
| SCI | 31.4% | 21.8% | 12.0% | .012* | .547 | .017* |
| eICA stenosis | 5.9% | 7.3% | 18.1% | .066 | .082 | .021* |
| Characteristic . | TP1, mean (SD) . | HU+TP2, mean (SD) . | None, mean (SD) . | Comparison (P) . | ||
|---|---|---|---|---|---|---|
| Intracranial macrovasculopathy (n = 51) . | Frequent VOC/ACS (n = 55) . | Less severe (n = 83) . | TP1 vs none . | HU+TP2 vs none . | Intensified vs none . | |
| White blood cell | 16.5 (5.5) | 14.4 (4.7) | 13.2 (4.1) | .001* | .152 | .002* |
| Hb | 7.7 (0.9) | 8.2 (1.2) | 8.5 (1.3) | <.001* | .124 | .002* |
| Mean corpuscular volume | 80.5 (7.7) | 78.5 (9.3) | 75.9 (9.7) | .004* | .150 | .012* |
| Reticulocyte count | 363 (149) | 290 (100) | 256 (92) | <.001* | .071 | <.001* |
| Platelets | 345 (144) | 372 (153) | 344 (110) | .817 | .288 | .405 |
| LDH | 935 (396) | 826 (390) | 681 (293) | .002* | .058 | .001* |
| HbF | 14.4 (7.8) | 13.9 (7.1) | 17.7 (8.8) | .038* | .014* | .008* |
| AAE rate | 0.24 (0.44) | 0.21 (0.43) | 0.12 (0.26) | .082 | .182 | .044* |
| SCI | 31.4% | 21.8% | 12.0% | .012* | .547 | .017* |
| eICA stenosis | 5.9% | 7.3% | 18.1% | .066 | .082 | .021* |
TP1 is the group with cerebral macrovasculopathy: abnormal TCD (n = 49) or intracranial stenosis (n = 2). HU+TP2 is the group treated with HU (n = 31) or TP (n = 24) because frequent VOC/ACS or other complications in absence of cerebral macrovasculopathy. None is the nonintensified group because it has a less severe clinical profile.
Significant tests.